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Abstract 
Case reports and an open trial have reported promising responses to repetitive 
transcranial magnetic stimulation (rTMS) to prefrontal and tempero-parietal sites in 
patients with depersonalization disorder (DPD). We recently showed that a single 
session of rTMS to the ventrolateral prefrontal cortex (VLPFC) was associated with a 
reduction in symptoms and increase in physiological arousal. Seven patients with 
medication-resistant DSM-IV DPD received up to 20 sessions of right-sided rTMS to the 
VLPFC for 10 weeks. Stimulation was guided using neuronavigation software based on 
participants’ individual structural MRIs, and delivered at 110% of resting motor 
threshold. A session consisted of 1Hz repetitive TMS for 15 minutes. The primary 
outcome measure was reduction in depersonalization symptoms on the Cambridge 
Depersonalisation Scale (CDS). Secondary outcomes included scores on the Beck 
Depression Inventory (BDI) and Beck Anxiety Inventory (BAI). 20 sessions of rTMS 
treatment to right VLPFC significantly reduced scores on the CDS by on average 44% 
(range 2 - 83.5%). Two patients could be classified as “full responders”, four as “partial” 
and one a non-responder.  Response usually occurred within the first 6 sessions. There 
were no significant adverse events. A randomized controlled clinical trial of VLPFC rTMS 
for DPD is warranted.  
 
Key words: Depersonalization Disorder; Repetitive transcranial magnetic stimulation; 
Prefrontal cortex; Case Series. 
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1. Introduction 
Depersonalization/derealization is defined in the DSM-IV as “persistent or 
recurrent experiences of feeling detached from, and as if one is an outside observer of, 
one’s mental processes or body (e.g., feeling like one is in a dream)” (American 
Psychiatric Association, 1994)a. More specifically, depersonalization disorder (DPD) is 
characterized by distressing feelings of unreality and alterations in a person’s sense of 
self (Sierra, 2009). The condition is estimated to have an incidence rate at around 1% 
(Lee et al., 2012; Michal et al., 2009) of the population. It commonly begins around early 
adulthood (Baker et al., 2003) and has a tendency to be long-lasting (Simeon et al., 
2003). It can appear as a symptom of other psychiatric disorders (Sierra et al., 2012), 
including approximately 12% of cases of panic disorder (Simeon et al., 2003). The 
symptom of depersonalization is commonly described in patients with neurological 
conditions, especially temporal lobe epilepsy (Lambert et al., 2002) and also following 
substance misuse (Medford et al., 2003; Simeon et al., 2009). A variety of 
pharmacological treatments have been tried (Sierra et al., 2006) but for the most part 
have not delivered sufficient significant improvement to patients (Baker et al., 2003; 
Simeon et al., 2003). Research into psychological treatments are lacking; however a 
cognitive behavioral model has been developed (Hunter et al., 2003, 2005). 
 
1.1. rTMS and DPD 
There have been two case reports, and one trial reporting the effects of TMS in 
DPD. In the first 1Hz repetitive TMS of the dorsolateral prefrontal cortex was used 
(Keenan et al., 1999) and this was reported to have increased the patient’s self-
awareness and reduced depersonalization symptoms. In a second case study, a 24 year-
old male with comorbid DPD and major depression who had not responded to 
pharmacotherapy (Jiménez-Genchi, 2004) was given left DLPFC rTMS thrice weekly. 
After six sessions, a 28% reduction in symptoms was reported. Finally, a trial in twelve 
DPD patients reported that half of the participants responded to temporal parietal 
junction (TPJ) TMS after three weeks of treatment (Mantovani et al., 2011). The TPJ 
region was chosen due to its relevance in out of body experiences (Blanke et al., 2005; 
Simeon et al., 2000). Five out of the six responders showed a 68% reduction in 
symptoms after a total of six weeks treatment. Unfortunately, none of these studies 
utilized either a sham or active control condition, so it is not possible to exclude placebo 
effects.  
                                                        
a The DSM-5 has renamed the syndrome Depersonalization/Derealization Disorder 
(DDD). 
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We have recently explored the effect of rTMS to the ventro-lateral prefrontal 
cortex (VLPFC) (Jay et al., 2014). A neurobiological model has also been proposed 
(Sierra and Berrios, 1998), hypothesizing dysfunctionally increased fronto-
insula/limbic inhibitory regulation. This model is consistent with neurological case 
studies (Lambert et al., 2002) and has been refined by neuroimaging research using 
fMRI (Lemche et al., 2007; Phillips et al., 2001), which has demonstrated reduced insula, 
limbic and visual association cortical activation in response to emotive pictures, and 
increased VLPFC activation. In the recent study we hypothesized that inhibition to right 
VLPFC using low frequency (LF) rTMS would lead to increased arousal and reduced 
symptoms (Jay et al., 2014). Seventeen patients with DPD and healthy controls were 
randomized to receive one session of right-sided rTMS to VLPFC or temporo-parietal 
junction (TPJ). Patients showed increased electrodermal capacity, suggesting increased 
physiological arousal after VLPFC rTMS only, although both groups showed 
symptomatic improvements, at least immediately post TMS.  We concluded that TMS is a 
potential therapeutic option for DPD and that modulation of VLPFC is a plausible 
mechanism. Most recently the occurrence of depersonalization symptoms has been 
reported following high frequency (HF), i.e. stimulatory rTMS to the dorsolateral PFC in 
a woman with treatment-resistant depression (Geerts et al., 2015) which is consistent 
with the model. 
 
2. Methods 
2.1. Design 
This study employed a consecutive ‘case-series’ design with before and after 
measures.  
 
2.2. Participants 
There were N = 7 participants in total (N = 5 were male) recruited through the 
Depersonalisation Unit Clinic, a specialist tertiary care outpatients service based at the 
Maudsley Hospital, South London. All patients had a primary diagnosis of DPD (DSM IV-
TR) following interview by the clinic psychiatrist. All were given a copy of an 
Information Sheet explaining the purpose of the trial and the basic working of rTMS. 
Participants were informed that they were being offered multiple sessions of an off-label 
experimental treatment and that they could withdraw from the trial at any time and 
without giving a reason.  
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Inclusion criteria included a current primary diagnosis of DPD with scores ≥70 
on the Cambridge Depersonalization Scale (Sierra and Berrios, 2000) and ability to 
provide written informed-consent. Exclusion criteria were personal history of migraine 
or severe headaches, a current or historical neurological diagnosis, a personal or family 
history of seizures, any medical condition involving a loss of consciousness, or 
contraindications to MRI. All were unresponsive to at least one medication, although 
most had failed to respond to several and had been ill for at least 2 years. Patients taking 
medications could participate in the trial if their medication did not have safety 
contraindications with rTMS (Rossi et al., 2009) and if they had been on a stable dose for 
at least two weeks. None were currently receiving co-current psychotherapy.   
 
A structural MRI was obtained for all participants prior to rTMS. MRI data were 
acquired on a GE 1.5 Tesla HDx system (General Electric, Milwaukee, WI, USA) at the 
Institute of Psychiatry, London. Localiser and calibration scans were followed by 2D T2-
weighted Fast Spin Echo and FLAIR (Fluid Attenuated Inversion Recovery) scans. A 3D 
T1-weighted Inversion Recovery prepared Spoiled Gradient Echo (IR-SPGR) scan was 
then collected with the following parameters: TE = 5 ms; TR = 12 ms; TI = 300 ms; 
excitation flip angle=18 degrees; matrix size 320x224x220 over a 288x202x198 Field of 
View, giving an isotropic 0.9 mm voxel size over the whole brain. Images were 
converted to DICOM format for use within BrainSight 2, a widely used neuronavigation 
software program (Herwig et al., 2001) which ensures that stimulation can only be 
delivered when the target site is positioned using the frameless stereotaxy.  
2.3. TMS protocol 
Resting motor threshold (MT) in M1, defined as the lowest intensity of TMS 
which yielded motor-evoked potentials (MEPs) of at least 50 µV in 5 out of 10 trials 
using an MEP pod, was determined from electromyographic (EMG) activity in the 
abductor pollicis brevis using surface electrodes. Co-registration of the participant with 
their MRI scan and BrainSight 2 (Rogue Research, Montreal), and coil calibration were 
performed. The ‘target site’ of right VLPFC for stimulation using the Simple Point 
method was prepared prior to the participant’s arrival by entering their Talairach 
coordinates. The coordinates (x = 35, y = 25, z = -7) were chosen to correspond to 
Brodmann Area (BA) 47 (which were previously found to be active in only patients with 
a diagnosis of DPD in response to aversive scenes in an fMRI task (Phillips et al., 2001)). 
The coil was held tangential to the scalp of the head with the handle pointing back away 
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from midline at 45˚. Each session participants received 15 minutes rTMS delivered at 1 
Hz and 110% MT to the right VLPFC using a Magstim RMA6802, 3014-00 Rapid² Dual 
PSU figure-of-eight coil (Magstim Co. Ltd., UK) – i.e. 900 pulses per session. Following 
TMS, outcome measures were completed plus a side-effects checklist. 
2.4. Outcome measures 
Socio-demographic variables were recorded for all participants. At baseline, all 
participants completed the CDS, a self-assessment instrument with good reliability and 
validity which has state and trait versions (CDS-S and CDS-T, respectively). A score of 70 
(out of maximum 290, CDS-T) has a sensitivity of 75.5% and specificity of 87.2% as a 
clinical cut-off (Sierra and Berrios, 2000). The CDS-S adapts 22 of the 29 items which 
lend themselves to a ‘here and now’ rating and uses the mean score expressed as a 
percentage. While the CDS-T requires scores on a 1-10 Likert scale for each item (a 
combination of frequency and duration ratings) and the total score expressed as a sum, 
the CDS-S is measured in 1-100% and the total expressed as a mean value. The scale has 
high reliability and internal consistency and has been shown to be sensitive to symptom 
change (Hunter et al., 2005). Participants also completed the Beck Depression Inventory 
(Beck et al., 1961), Beck Anxiety Inventory (Beck et al., 1988) and the Dissociative 
Experiences Scale (Bernstein and Putnam, 1986).  
 
Patients received two sessions weekly, which were evenly spaced throughout 
the week for participants’ convenience. At each session symptoms of depersonalization 
were measured using the self-report version of the CDS-S immediately before and after 
TMS as well as a safety checklist post rTMS. At the last session, participants completed a 
CDS-T, BAI, BDI, and DES as final outcome measures. The CDS-S was the primary 
outcome measure. 
Analyses were descriptive given the sample size with illustrative paired t-tests. 
Response rates were calculated according to percentage reductions in CDS-S score; 
reductions on the CDS-S of at least 50% were classed as a ‘full response’ and reductions 
of 25% or more were classed as ‘partial response’ (Mantovani et al., 2011). 
 
3. Results  
3.1. Demographic characteristics 
Patients 1 – 7 completed a full course of treatment (i.e., a total of 17 – 20 sessions). 
Three of the participants were taking psychotropic medication to include selective-
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serotonin-reuptake-inhibitors with or without the augmentation of lamotrigine (all >6 
months). Patients differed little in their age of onset (Table 1). 
 
3.2. Outcome measures 
Clinical psychopathology measures at baseline and trial completion are shown in Tables 
2 & 3. Depersonalisation symptom scores (CDS-S) fell by 44.4% overall, although there 
were large individual differences in CDS-S score change (range 2.3% to 83.5%) (see 
Table 3). Paired t-tests showed that the change in scores was significant (p = 0.03, t = 
2.92, df = 6). It appears that anxiety symptom scores fell somewhat (paired t-tests, NS), 
whilst scores on depression and general dissociation symptom measures did not 
change. Treatment progress session by session for a single case is shown in Figure 2. 
 
Total percentage reductions in CDS-S scores were calculated for each patient. 
We used criteria applied in a previous rTMS trial for DPD (Mantovani et al., 2011). After 
one session, 5 out of 7 patients showed a ‘partial response’ according to these criteria, 
and after trial completion, 2 out of 7 patients showed a ‘full response’ (see Table 3). A 
paired t-test was significant at the 5%-level: t(6) = 2.92, p = 0.03. 
Case Vignette 
Patient 2: A 40-year-old unemployed male with longstanding depersonalization, 
accompanied by low mood and a history of alcohol misuse. He had neither 
responded to several prescribed pharmacotherapies, nor cognitive behavioural 
therapy. Depersonalization began gradually in the context of panic attacks 
associated with agoraphobia, which later took on a permanence, replacing the 
panic attacks altogether. He felt cut-off from the world, emotionally numb, things 
appeared unreal, and he experienced feelings of lack of agency, ‘being on auto-
pilot’. After the first TMS session the patient described feeling “noticeably more 
awake and ‘switched on’”. Half way through the second treatment, the patient 
experienced feelings of “increased wakefulness” and “being more cheerful”. Half 
way through his treatment course the patient spontaneously reported that on a 
train journeying back from a session, the faces of strangers and commuters 
appeared “threatening”. He also reported increases in hearing clarity and 
appetite. One possible negative consequence of TMS treatment was a transient 
change in drinking behavior “to calm myself a little”.  
 
 
3.3. Adverse and Side-effects 
All patients completed a side-effects checklist after every rTMS session 
encompassing pleasant as well as unpleasant side effects. Two patients 
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experienced a mild headache. One also experienced pain above his left eye on 
two occasions.  
 
Whilst we did not measure disinhibitory behavior directly, on some 
occasions patients appeared to display examples of such behavior immediately 
after an rTMS session. This included: (i) putting on the physician’s jacket (ii) 
labile affect (iii) spontaneous laughter with no clear origin, and (iv) discussing 
provocative subjects spontaneously. Similar examples are referred to in the 
rTMS side-effects literature (Wassermann, 1998). None of these instances were 
long-lasting or of clinical concern. 
 
4. Discussion 
 
Data presented in this case series indicate that 1Hz rTMS to the right VLPFC may 
be a potential treatment option for DPD, which has previously proved difficult to treat 
with pharmacotherapy. Six out of seven participants showed over 25% improvement in 
symptoms, two over 50%. One participant did not respond to treatment. Key outcome 
measures in this study were scores on the CDS-S and other standardized 
measures, however patients commented that these scales did not always capture 
all the phenomenological changes they were experiencing.  
 Findings indicate that a single session of right-sided VLPFC 1Hz 
stimulation can reduce scores on the CDS-S, but these scores tend to fall further 
following multiple sessions of this treatment (see Figure 1). General symptoms 
of dissociation (DES) were not affected attesting to the specificity of the 
intervention for DPD. Patient responses are quite individual when examined in 
detail (see Figure 2); 20 sessions may be more than is required for maximum 
benefits to be realized with much benefit appearing after the first 1-5 sessions.  
TMS may act via biological mechanisms different to that of psychotropic 
medications and as such make it a potentially new treatment method for the 
disorder. Multiple sessions of rTMS to the right VLPFC delivered at 1 Hz is 
tolerable and acceptable to patients. 
 
4.1. Limitations 
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Placebo effect in rTMS treatment is a complex issue exacerbated by the 
difficulty in creating a true sham condition (Broadbent et al., 2011; Rossi et al., 
2009). Our proof of concept study showed a single session of rTMS to TPJ and 
VLPFC both reduced symptoms although only with the latter was there 
concomitant changes in physiological arousal. This study could be interpreted as 
showing the potential value of stimulation to both sites in the alleviation of DPD, 
perhaps acting through different neural circuits or different point of the same 
circuits (for those for self-directed attention, or, emotional control (Corbetta and 
Shulman, 2002; Ochsner and Gross, 2005)). However, placebo effects cannot be 
ruled out without a sham condition with double-blind allocation (Broadbent et 
al., 2011). Hence a definite therapeutic effect for rTMS in this condition has not 
yet been proven. Patients included in case series studies are often selected 
because of their chronicity and their willingness to undergo novel approaches. 
Hence the generalizability of any results cannot be assumed. In addition, no 
clinician-rated outcome or more regular anxiety (BAI) / depression (BDI) 
measures were captured. 
 
4.2. Future directions 
The potential of rTMS as a treatment option for DPD requires further 
study in the form of a controlled trial of multiple sessions of rTMS. If further 
sham-controlled research proves positive, rTMS may be judged an appropriate 
intervention or adjunct to other interventions e.g. antidepressants. Combining 
treatment studies with investigations of mechanisms using neurophysiological 
and neuroimaging techniques for example would also lead to rapid advances in 
the field. Finally, the optimal delivery of rTMS for therapeutic purposes such as 
the spacing and number of sessions also requires further study. 
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Figure 1. Scores on the CDS (State Version) for Cases 1-7. 
 
 
Figure 1. Mean scores with error bars (SDs) on the CDS-S for all 7 participants at three 
time points of the TMS treatment. 
 
 
Figure 2. Scores on the CDS (State Version) for Case 4. 
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Figure 2. Full treatment progression with TMS giving pre- and post-session scores for 
Case 4 on the CDS-S. *Please note that the pre-session score for meeting no. 3 is missing. 
 
Table 1. Demographic information for patients in series (n=7). 
 
 
 
 
 
0
10
20
30
40
50
60
CDS-S Mean (Case 4) 
Trial participants diagnosed with DPD (Mean, SD) 
Age, years 36.1 (12.7) 
Gender N=5 Male : N=2 Female 
Duration of DPD illness, years 19.4 (18.5) 
Age of DPD onset, years 16.6 (6.1) 
CDS-Trait Score 123.4 (35.9) 
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Table 2. Clinical measures at baseline and post rTMS trial. 
Psychopathology ratings pre and post rTMS - (Means (SD)) 
N=7 
  
 Pre rTMS End of rTMS 
trial 
Reduction in 
% 
t p 
BDI 18.0 (9.0) 15.3 (11.9) 15.0 1.94 > 0.10 
BAI 13.4 (11.8) 9.6 (7.2) 28.4 1.92 > 0.10 
DES 20.2 (11.5) 20.2 (10.5) 0.0 0.19 > 0.85 
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Table 3. Response rates and pre/post TMS scores on Cambridge Depersonalisation Scale (CDS) 
for all 7 cases. 
CASE CDS – Trait 
(Baseline) 
CDS – State 
(Baseline) 
 CDS – State 
Post-Trial 
Reduction 
on CDS – 
State (%) 
Response 
Post-Trial 
1 166 36.0  23.8 33.9 Partial 
2 110 61.7  10.2 83.5 Full 
3 164 32.7  15.2 53.5 Full 
4 138 43.6   42.6 2.3 Non 
5 83 25.1  13.5 46.2 Partial 
6 127 51.2  29.2 42.9 Partial 
7 76 19.6  10.1 48.3 Partial 
Series 
Mean (SD) 
123.4 (35.9) 38.6 (14.7)  20.7 (12.0) 44.4 (24.2) n/a 
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Highlights 
 Depersonalization is characterized by feelings of derealisation and detachment. 
 There are no reliably effective treatments available for people with the condition. 
 The present rTMS treatment led to symptom improvement in 6 out of 7 cases. 
 Participants reported few side-effects. 
 
